Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
Interventions: Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections, Standard Wound Care; Device · Procedure
Lead sponsor: Arteriocyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 6
States / cities: Bakersfield, California • Idaho Falls, Idaho • Englewood, New Jersey + 3 more

Conditions: Sexual Dysfunction, Bipolar Disorder
Interventions: Maca Root, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Anaheim, California • Hallandale, Florida • Hollywood, Florida + 7 more

Conditions: Alcohol Withdrawal, Alcohol Withdrawal Delirium
Interventions: Phenobarbital, Lorazepam; Drug
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Lunsekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 942 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 75
States / cities: Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 61 more

Conditions: Wounds and Injuries
Interventions: Embolization; Procedure
Lead sponsor: Oslo University Hospital; Other
Eligibility: 16 Years to 80 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Denver, Colorado • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: ACTH, Placebo; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more

Conditions: Migraine
Interventions: Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 30
States / cities: Tempe, Arizona • Colton, California • Los Angeles, California + 27 more

Conditions: Knee Osteoarthritis
Interventions: CNTX-4975-05, Lidocaine without epinephrine, ElastoGel, Breg Ice Water Pump; Drug · Device
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 24 more

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Ruxolitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 88
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more

Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Interventions: Placebo, MORF-057; Drug
Lead sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 25
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more

Conditions: Infertility
Interventions: in vitro fertilization (IVF/ICSI); Other
Lead sponsor: New Hope Fertility Center; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Uveitis
Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab); Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more

Conditions: Body Weight Changes
Interventions: MicroDiet, Healthy Diet; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hypertension, Obesity
Interventions: Soft Commitment Device; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Portal
Interventions: Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more

Conditions: IUD Insertion Pain
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Hillsborough, North Carolina

Conditions: HIV Infections
Interventions: Cemiplimab, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina

Conditions: Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions: LV305, G305, LV305-matching placebo, G305-matching placebo; Biological · Other
Lead sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized, Bipolar Disorder (BPD)
Interventions: Prescription Psychotropic Medications; Drug
Lead sponsor: Gaize; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor; Biological · Drug · Procedure
Lead sponsor: Kiadis Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: Neonatal Abstinence Syndrome
Interventions: High-calorie formula; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: ACL Injury
Interventions: Blood Flow Restriction (BFR) therapy, Standard REHAB; Other
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 15 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Colitis, Ulcerative
Interventions: Combined Anti-inflammatory Diet (CAID); Behavioral
Lead sponsor: Transparency Life Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Brookline, Massachusetts

Search by objective public record fields.

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females

A Study of V132 in Healthy Older Participants (V132-001)

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Splenic Injury Embolization - the Question About NOM (SInE Qua NOM)

ACTH for Fatigue in Multiple Sclerosis Patients

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

IVF Clinical Trial of Two Different Treatment Protocols.

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet

Intermittent Fasting Adherence and Self Tracking

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Oral Ketorolac for IUD Pain Reduction

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants

BFR Therapy for Post-Op Rehab of ACL Reconstruction With Quadriceps Tendon Autograft

Decentralized Dietary UC Pilot Trial